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Abstract
During the past 10  years, major progress has been accomplished with the
discovery of activating mutations that are associated with the vast majority
of BCR-ABL negative human myeloproliferative neoplasms (MPNs). The
identification in 2005 of JAK2 V617F triggered great interest in the JAK2-STAT5/
STAT3 pathway. Discovery in 2006 of mutants of thrombopoietin receptor (TPO-
R/MPL) and later on of mutants in negative regulators of JAK-STAT pathway
led to the notion that persistent JAK2 activation is a hallmark of MPNs. In 2013,
mutations in the gene coding for the chaperone calreticulin were reported in
20-30 % of essential thrombocythemia and primary myelofibrosis patients. Here,
we will address the question: what do we know about calreticulin that could help
us understand its role in MPNs? In addition to oncogenic driver mutations, certain
MPNs also exhibit epigenetic mutations. Targeting of both oncogenic drivers and
epigenetic defects could be required for effective therapy.
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Abstract During the past 10 years, major progress has been
accomplished with the discovery of activating mutations that
are associated with the vast majority of BCR-ABL negative
human myeloproliferative neoplasms (MPNs). The identifica-
tion in 2005 of JAK2 V617F triggered great interest in the
JAK2-STAT5/STAT3 pathway. Discovery in 2006 of mutants
of thrombopoietin receptor (TPO-R/MPL) and later on of mu-
tants in negative regulators of JAK-STAT pathway led to the
notion that persistent JAK2 activation is a hallmark of MPNs.
In 2013, mutations in the gene coding for the chaperone
calreticulin were reported in 20–30 % of essential
thrombocythemia and primary myelofibrosis patients. Here,
we will address the question: what do we know about
calreticulin that could help us understand its role in MPNs?
In addition to oncogenic driver mutations, certain MPNs also
exhibit epigenetic mutations. Targeting of both oncogenic
drivers and epigenetic defects could be required for effective
therapy.
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Introduction
Myeloproliferative neoplasms (MPN) are a group of chronic
hematological malignancies characterized by the over-
production of mature blood cells such as erythrocytes,
granulocytes, and/or platelets [1]. Chronic myeloid leukemia
(CML) was differentiated early from otherMPN following the
discovery of Philadelphia chromosome and BCR-ABL1 fu-
sion genes. Over several decades and in the absence of spe-
cific molecular defects, other MPN have been grouped in the
Philadelphia negative MPN subgroup, with various entities
depending on clinical and biological features. Polycythemia
vera (PV) is characterized by an increased red cell production,
essential thrombocythemia (ET) displays thrombocytosis,
while primary myelofibrosis (MF) is characterized by spleno-
megaly and early bone marrow fibrosis due to scarring in-
duced by highly proliferating myeloid progenitors and patho-
logical stimulation of local fibroblasts. The natural history of
MPN is characterized by the risk of thrombotic events and
transformation into acute myeloid leukemia (AML), a highly
severe evolution associatedwith a dismal outcome. PVand ET
may also evolve towards secondary myelofibrosis, spleno-
megaly, and pancytopenia. In the past years, the main thera-
peutic goal has been to prevent thrombotic events through the
normalization of peripheral blood cell counts and the use of
antiplatelet drugs. The discovery of somatic driver mutations,
associated epigenetic regulator mutations, and abnormal sig-
naling pathways has paved the way to a better understanding
of MPN pathogenesis and eventually establishing innovative
therapeutic strategies [1].
The Cytokine Receptor-JAK-STAT Pathway
The cytokine receptor-JAK-STAT pathway is a key signaling
pathway during myelopoiesis. As a consequence, it is no
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surprise to see that this pathway also plays a crucial role in
MPN pathogenesis. Cytokines such as erythropoietin (EPO),
thrombopoietin (TPO) or granulocyte colony-stimulating fac-
tor (GCSF) bind to their respective receptor—EPO-R, TPO-
R, or GCSF-R—on progenitor cells to regulate erythropoiesis,
megakaryopoiesis, or granulopoiesis. TPO-R and GCSF-R
are also expressed by hematopoietic stem cells. The cytoplas-
mic domains of these receptors are docking sites for Janus
kinases (JAK). JAK2 is one of the four JAKs, which contain
an N-terminal FERM domain, a Src-homology like domain
(SH2), a pseudokinase domain (JH2), and a C-term kinase
domain (JH1) [2•]. The FERM and SH2 domains anchor
JAK2 to cytokine receptors, JH2 regulates kinase activity, while
JH1 is responsible for tyrosine phosphorylation. Following the
binding of cytokines to their receptor, a change in receptor
conformation takes place so that JAK2 phosphorylates in trans
Y1007 and Y1008 in the activation loop of the JH1 domain,
thus inducing JAK2 activation. JAK2 phosphorylates cytokine
receptors and signal transducers and activators of transcription
(STAT) bind to phosphorylated tyrosine residues on these cy-
tokine receptors through their SH2 domains whereupon JAKs
can themselves be phosphorylated by JAKs [1]. Phosphorylat-
ed STATs can translocate into the nucleus to be part of tran-
scriptional complexes. In addition to activating STATs, JAKs
also activate the phosphatidylinositol 3 kinase (PI3K)/AKTand
the Ras-MAP kinase-ERK pathways. These three pathways
induce survival, proliferation, and myeloid differentiation.
Somatic Mutations
Three Driving Mutations are Responsible for MPN
Development
In the last 10 years, three classes of main somatic driving
mutations have been identified in MPN, from JAK2
(JAK2V617F), TPO-R (TPO-RW515) to more recent
calreticulin (CALR) mutations (Table 1). Overall, these three
mutations account for 90–95 % of MPN and are most often
mutually exclusive [3••, 4••, 5•]. JAK2 mutations are found in
all PV cases and in around 60 % of MF and ET cases. The
JAK2 V617F mutation accounts for 97 % of PV cases, while
JAK2 exon 12 mutations around K539 are found in the 3 %
remaining cases of PV [6–10]. JAK2 V617F arises in exon 14
of JAK2 on 9p chromosome. The guanine-to-thymidine mu-
tation induces the substitution of valine for phenylalanine at
position 617 in the pseudokinase JH2 (JAK homology domain
Table 1 Driving mutations in MPN
Frequency in MPN Clinical characteristicsa Clinical outcomea
JAK2 V617F PV ≈ 97% - Median OS (PV) ≈ 13 years [50]
ET ≈ 60% Median OS (ET) ≈ 20 years [50]
MF ≈ 60% Median OS (MF) ≈ 5-9 years [49, 50]
Exon 12 JAK2 mutations PV ≈ 3% Younger patients,
isolated erythrocytosis [75], WBC
and platelets counts are
often normal [75]
Compared to JAK2V617F PV, similar
thrombotic and transformation risks [75]
TPO-RW515L/K/A PV≈ 0
ET ≈ 1% ET: increased platelet count,
decreased Hb [50]
ET: no impact on outcome
MF ≈ 5% MF: younger, lower WBC [50],
anemia more frequent
MF: Similar outcome compared to
JAK2V617F MF [49, 50]
CALR PV ≈ 0
ET ≈ 25% ET: male and younger patients,
increased platelet count, lower Hb
levels [41, 50]
ET: low thrombotic risk, no impact on
OS ≈ 20 years [50]
MF ≈ 30% MF: younger patients, lower WBC,
higher platelet count [49, 50]
MF: improved outcome (median OS ≈ 14 years)
for type I CALR mutations [50, 51]
Triple negative PV ≈ rare cases
ET ≈ 10 to 15% ET: younger age, lower Hb, lower
WBC [50]
ET: lower thrombotic risk, no impact on
outcome [50]
MF ≈ 10 to 15% MF: lower Hb [49, 50] MF: poor outcome (median OS≈2.5 years),
higher transformation risk [49, 50]
OS overall survival, Hb hemoglobin level, WBC white blood cell counts, PV polycythemia vera, ET essential thrombocythemia, MF myelofibrosis
a For exon 12 JAK2, CALR, TPO-R or triple negative mutations, clinical characteristics and outcome were compared to JAK2V617F cases
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2 or pseudokinase) domain [2•]. This mutation rigidifies the α
helix C in the JH2 domain to promote the transphosphorylation
of JH1 [2•]. The precise mechanism of conformational change
in JH2 induced by V617F is represented by aromatic interac-
tion between F617, F595, and F594 in the helix C of the JH2;
an aromatic residue is required both on helix C and at position
F595 for constitutive activity [11, 12]. Tyr 1007 and Tyr1008
in JH1 (kinase domain) are phosphorylated, so that
JAK2V617F is constitutively active in the absence of cytokine
[13]. Of note, JAK2V617F needs the presence of cytokine
receptors—especially TPO-R—to be constitutively active, as
the deletion of TPO-R significantly reduces MPN phenotype
in vitro and in vivo [14]. The transphosphorylation of JAK2
induces constitutive activation of STATs in the absence of cy-
tokine, thus contributing to the cytokine-independent growth
of hematopoietic progenitors in methylcellulose assays.
Amongst various STATs, STAT5A and STAT5B play a crucial
role in MPN pathogenesis, as deletion of both Stat5 a/b genes
abrogates the PV phenotype in JAK2V617F mouse models
[15, 16]. Noteworthy, STAT5 DNA binding sites differ be-
tween cytokine activated and constitutively activated STAT5
because constitutively active STAT5 binds to low affinity γ
interferon activated sites [17]. Constitutively activated STAT5
also recruits TP53 in a transcriptional complex at specific
STAT5-TP53 genomic promoters to induce the expression of
specific genes such as miR-28, which targets and
downregulates TPO-R expression [18, 19]. As such, target
genes of the STAT5-TP53 complex differ from target genes
of STAT5 or TP53 taken alone. These two mechanisms con-
tribute to the development of a specific gene expression profile
in MPN. On the contrary, STAT1 and STAT3 impact on the
specific MPN which arises following JAK2 V617F mutation.
STAT1 promotes an ET-like phenotype possibly through in-
creased levels of Interferon γ because deletion of Stat1 impairs
megakaryopoiesis and promotes erythropoiesis in a condition-
al JAK2 V617Fmurine model [20]. Conversely, Stat3 deletion
increases thrombocytosis in conditional JAK2 V617F mice
[21]. PI3 kinase activation by JAK2 V617F also triggers rep-
lication defects with an altered intra-S checkpoint response and
a replication fork stalling [22]. JAK2 V617F mutation results
in a monoclonal population in human MPN, and the presence
of JAK2 V617F in a single LSK cell is sufficient to induce
MPN in a murine model [23]. Whether JAK2 V617F progen-
itor and stem cells display a growth advantage over wild-type
hematopoietic stem and progenitor cells has been a matter of
debate [23–25].
Mutations of TPO-R can be found in around 5 % of MF
and 4% of ET patients [26, 27]. These mutations occur mainly
at position W515 in an amphipathic RWQFP domain of the
human receptor at the junction between the transmembrane
and the cytoplasmic domains, which is required for
maintaining the TPO-R inactive in the absence of ligand
[28]. While W515 prevents TPO-R dimerization in the ab-
sence of TPO, the substitution of tryptophan for leucine, ly-
sine, arginine, serine, or others induces constitutive TPO-R
dimerization and activation of TPO-R [29]. In vivo pathoge-
nicity of TPO-RW515 mutants requires Tyr 626 of the cyto-
solic domain that links the receptor to MAP-kinase and
STAT3 [30]. Another mutation that is found in familial and
rare sporadic ET is the transmembrane S505N human TPO-R
mutation, which induces an active orientation of the trans-
membrane domain of TPO-R [29].
In 2013, a third driver mutation, occurring in the gene
CALR was discovered in JAK2 wild type (WT) and TPO-R
WTMPN and accounts for 20 to 30% of ETandMF [3••, 4••].
CALR
What Do We Know About CALR?
CALR encodes calreticulin, a multifunctional 55 kDa chaper-
one protein localized in the endoplasmic reticulum (ER), that
is involved in calcium retention and protein folding, as well as
in immune responses, by the ability of CALR to be
translocated to the cell surface in apoptosing cells [31–34].
Although various CALR mutants (over 50) in exon 9 have
been described, the most frequent ones are a deletion of 52
base pairs or an insertion of 5 bases pairs in exon 9, denoted
del 52 (type 1) and ins 5 (type 2) [3••]. All detected mutations
induce a frameshift to the +1 frame, thus resulting in the same
novel positively charged sequence. Contrary to the wild-type
CALR, which contains at the C-terminus (coded by exon 9)
several stretches of negatively charged amino acids (KDEE)
involved in binding calcium with low affinity and high capac-
ity and a KDEL C-terminal motif, the CALR mutants contain
the novel positive amino acids and lack the KDEL ER reten-
tion motif at their C-terminus [3••]. Notably, granulocytes
with CALRmutation also display a JAK2 activation signature
and an enrichment of STAT5A/B target genes, thus showing
that common pathways triggerMPN pathogenesis irrespective
of JAK2 or CALRmutation [5•]. CALRmutated patients also
exhibit an increased expression of EZH2 and SUZ12, two
members of the polycomb repressive complex 2, suggesting
that epigenetic regulations might take place in CALRmutated
granulocytes compared to normal granulocytes [5•].
Of interest, both the wild type and MPN mutants of CALR
exhibit intact N-terminal and Proline-rich (P) domains (Fig. 1).
While CALR has been classically described as binding high
mannose immature N-glycosylated proteins of the ER that are
also monoglucosylated, there are both glycan-dependent and
glycan-independent interactions with protein substrates
[35–37]. The N-terminal domain is involved in both types of
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interaction, but for the latter, the P domain contributes to the
non/deglycosylated proteins [37]. Another ER chaperone,
ERp57, forms complexes with the P domain of CALR [37].
The X-ray structure of the globular lectin binding domain of
CALR has been solved, revealing a peptide binding area, and
indicating a multi-molecular (peptide and sugar binding)
mechanism [38, 39]. A long channel on CALR formed by a
concave β-sheet was shown to bind a tetrasaccharide [38].
Preliminary Evidence Linking CALR Mutants
to the JAK-STAT Pathway and MPN Phenotype
Transplantation of murine bone marrow transduced with retro-
viruses coding for del 52 and ins 5 CALRmutants results in an
MPN phenotype with thrombocytosis after week 13, which
can be propagated upon serial transplantation [40]. Subsequent
work demonstrated that the allele burden of CALR mutants
appears to be significantly higher in ET patients with CALR
mutations than in JAK2 V617F ET patients [41]. Given that
CALR mutated patients are younger, these differences suggest
that CALR mutants might have a more profound effect on
amplifying mutated stem cells, and that the disease penetrates
faster in the granulocytic compartment. With one exception,
where CALRmutation was found in a PV patient [42], the vast
majority of data indicate that CALR mutants are associated
with ET and MF and are mutually exclusive with TpoR and
JAK2 mutations [42, 3••]. In one recent report, a patient with
CML and thrombocytosis who remained thrombocytotic after
anti-ABL treatment was found to have an acquired CALR
mutation in a founding clone, where subsequently BCR-ABL
was acquired [43]. Treatment with ABL inhibitors targeted the
BCR-ABL positive clone but not the CALR mutated clone,
and the patient remained thrombocytotic [43]. Thus, CALR
mutations can be suspected in CML patients that remain
thrombocytotic after ABL inhibition.
The absence of the KDEL from the C-terminus of CALR
mutants would predict its localization in different cellular
compartments to wild-type CALR which via the KDEL re-
ceptor is retrieved and from Golgi and ER-to-Golgi vesicles
back to the ER. In one of the initial papers, describing the
CALR mutation in MPN indeed the mutants were found to
lose co-localization with calnexin, a marker for the ER [3••].
Unpublished evidence from our group where CALR-/- fibro-
blasts were reconstituted with wild type, del 52 or ins 5 CALR
mutants shows also that the mutants CALRs exhibit different
localization from wild-type ER and that they are able to leave
Fig. 1 Calreticulin (CALR) protein structure and functions. CALR is
located in the lumen of the endoplasmic reticulum. It contains a globular
N-terminal domain that is responsible for sugar binding, a proline-rich (P)
domain (also denoted the P-arm), which attracts the ERp57 chaperone
and promotes peptide binding, and a C-terminal domain coded by exon 9
which contains a high frequency of negatively charged aspartic and
glutamic amino acids that are involved in low affinity high capacity
calcium binding. At the C-terminus of the wild-type sequence (black),
there is a KDEL ER retention sequence. In contrast, in the MPN-
associated CALR mutants, the C-terminal sequence is changed for a
sequence that contains several positively charged amino acids like argi-
nine and lysine, and at the C-terminus, there is no KDEL ER retention
sequence. Certain functions of CALR are depicted, from the classical
chaperone function linked to binding monoglucosylated high mannose
Asn glycosylated proteins to novel functions, such as exposure on the cell
surface on apoptosing cells and stimulation of immunogenic cell death.
The mechanism by which wild-type CALR can be translocated to the cell
surface is not known
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the ER (Pecquet et al., unpublished). However, in the other
initial report, CALR mutants were shown to continue to be
localized in the ER [4••]. In this particular report, fusion pro-
teins between CALR mutants and GFP were used, and such
fusions might influence traffic [4••].
Also in the first report, evidence was provided that CALR
mutants activate the JAK-STAT pathway [3••]. Retroviral ex-
pression of CALR mutants, but not wild-type CALR in the
IL3-dependent proB Ba/F3 cell line, led to appearance of cells
that grew autonomously and, especially for the del 52 CALR
mutant, STAT5 activation could be demonstrated, although
weak [3••]. These cells were sensitive to JAK2 inhibitors
[3••]. Thus, it appears that CALR mutants can directly or
indirectly activate JAK2. This is supported by data from clin-
ical trials where patients with CALR mutations responded to
JAK2 inhibitors and to type I interferon, like JAK2 V617F
positive MPN [44, 45]; the question of course remains what
the precise mechanisms behind this effect might be. In addi-
tion, CALR mutants are predicted to profoundly influence
calcium homeostasis and reduce calcium reserves in the ER.
This, in turn, might mis-regulate nuclear factor of activated T
cells (NFAT) activation (de-phosphorylation), which allows
NFAT to be translocated to the nucleus and regulate
transcription.
Evidence Against a Major Role For JAK-STAT Pathway
in the Oncogenic Effect of CALR Mutants
One leukemia cell line, MARIMO, was found to harbor del 61
CALR, which exhibits the same frameshift and is a non-typ-
ical, but pathogenic CALR mutation [46]. In these cells, there
is no detectable activation of the JAK-STAT pathway, and
levels of JAK2 are very low. In contrast, these cells appear
to exhibit high MAP-kinase activation. Absence of JAK-
STAT activation in the presence of this mutation was
interpreted as evidence that JAK-STAT pathway is not key
for the oncogenic action of CALR mutants [46]. However,
this cell line has been derived from a leukemia patient that
previously had ETand was treated with Busulfan and exhibits
MYC amplification [47]. Thus, proliferation of MARIMO
cells might not need pathologic JAK-STAT signaling.
Differential Association of CALR Type 1 and Type 2
Mutations With Myelofibrosis and Essential
Thrombocytemia
The type 1 CALRmutation (del 52) seems to result in signaling
at higher levels than the type 2 (ins 5) mutation, based on the
first in vitro and in vivo studies [3••, 40]. Perhaps predictably,
the type 1 mutation is significantly more frequent inMF than in
ET [3••, 48], while the type 2 is more frequent in ET than inMF
[48]. This supports the notion that higher pathogenic signaling
leads to progression toMF, like in the case of JAK2 V617F [1].
InMF, and contrary to ET, patients with CALRmutated display
an improved outcome compared to patients with JAK2V617F
mutation (Table 1) [49, 50]. Although type 2 CALRmutation is
less frequently associated with MF, when it is, it seems to in-
duce a less favorable evolution than type 1 CALR mutation
[51]. One explanation could be that a weaker mutation will
require and lead to selection for other mutations, possibly epi-
genetic; another would be that ins 5 CALR induces a qualita-
tively different signal than del 52 CALR. Further studies are
required to settle this issue.
Other Mutations Than Phenotypic Drivers Can Affect
MPN Outcome
Additional mutations are also found in MPN in association
with one of these driving mutations. These mutations may
affect epigenetic regulators such as Ten-eleven translocation
2 (TET2), DNMT3A, ASXL1, EZH2, or genes involved in
apoptosis such as TP53 [52•]. Genomic mutations have been
sequentially looked for in granulocytes of MPN patients using
targeted next-generation sequencing [52•]. Surprisingly, most
mutations were already found at diagnosis, and only two so-
matic mutations occurred over a cumulative period of 133
patient-years [52•]. MPN cells turn out to be highly stable
from a genomic point of view [52•]. The clinical outcome
may therefore be predicted from somatic mutations found at
diagnosis [52•]. In particular, the more mutations at diagnosis,
the poorer long term outcome [52•]. The coexistence of vari-
ous mutations at diagnosis drives clonal heterogeneity and
evolution during disease natural history [52•, 53].
Ten-eleven translocation TET2 mutations were first de-
scribed in myeloid malignancies in 2009, notably in MPN
patients with heterozygous JAK2 V617F mutations [54].
The TET2 enzyme catalyzes the oxidation of 5-
methylcytosine to 5-hydroxymethylcytosine and subsequent-
ly to 5-formylcytosine and 5-carboxylcytosine and initiates
DNA demethylation [55]. TET2 mutations may occur before
or after driving mutations, thus giving rise to the coexistence
of various clones at the same time [52•, 56]. Loss of TET2
induces an increased proliferation of hematopoietic stem cells
(HSC) and confers to JAK2 V617F HSC a competitive ad-
vantage over JAK2 V617F/TET2 wild type HSC [56–58].
Whether TET2 mutations are associated with an adverse out-
come and a higher risk of transformation is controversial [52•,
59]. Of note, the order of occurrence between TET2 and
JAK2V617Fmutations matters and triggers distinct biological
and clinical effects [56]. Other mutations have been detected
in MPN patients. Mutations of DNMT3A—a DNA methyl-
transferase—have also been found in 5 % of MPN patients
[52•, 60]. EZH2 is a histone methyl transferase and a member
of the polycomb repressive complex 2, which induces the for-
mation of heterochromatin and participates in gene repression.
EZH2 loss of function mutations have been found in a few
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MPN cases (3 %) [52•, 61]. Other genes coding for chromatin
modifiers have been described in MPN, such as ASXL1 [62].
Other mutations have been found in AML transformation,
especially isocitrate dehydrogenase 1 and 2 (IDH1/2) [63]. Of
note, IDH1 mutations induce severe epigenetic defects [64].
TP53 mutations are highly associated with transformation
into AML [65]. Similarly, amplification of a region located on
1q region containing MDM4— encoding a p53 binding pro-
tein and inhibitor—is associated with AML transformation
[65]. When comparing paired chronic phase and transformed
MPN, an increase in TP53 variant allele frequency is observed
[53]. Chronic MPNs can be associated with heterozygous
TP53 mutations, while acquisition of homozygosity of TP53
mutation, or mutation of the other TP53 allele results is asso-
ciated with secondary acute myeloid leukemia [52•]. The
transplantation of TP53-/- JAK2 V617F bone marrow cells
in mice induces AML [53]. Of note, leukemic cells develop
from the megakaryocyte-erythroid progenitor cell population
[53]. Leukemic transformation results from the expansion of
the TP53 mutated clone and the loss of the WT allele [53].
Therapeutic Implications
The discovery of JAK2 V617F has paved the way to JAK2
inhibitors. Ruxolitinib is an ATP competitor and a potent
JAK1 and JAK2 inhibitor [66]. In two landmark clinical pa-
pers in 2012, ruxolitinib induced a spleen size reduction and a
relief of clinical symptoms in patients with myelofibrosis
compared to placebo (COMFORT I trial) or best available
therapy (COMFORT II trial) [67••, 68••]. These trials led to
the approval of ruxolitinib by the US and European adminis-
trations for the treatment of myelofibrosis. More recently, the
RESPONSE trial demonstrated that ruxolitinib was superior
to standard therapy to reduce hematocrit and reduce spleno-
megaly in patients with PV [69••]. Of note, the effectiveness
of ruxolitinib is not restricted to JAK2 V617F MPN and has
also been observed in JAK2 WT MPN. Whether ruxolitinib
will reduce AML transformation remains to be proven. While
ruxolitinib obviously improves the MPN armamentarium in
MPN therapy, the impact on allele burden is modest, a reduc-
tion of around 12 % after 32 weeks of therapy in the RE-
SPONSE trial [69••]. The very fact that ruxolitinib is not
JAK2 V617F specific and inhibits JAK2 WT may participate
in this limited activity. Beyond, other JAKs, JAK3 and TYK2
may also compensate for the inhibition of JAK1 and JAK2
activities [70]. Lastly, the microenvironment and especially
stromal cells may participate in the JAK inhibitor resistance
through the release of cytokines such as interleukin 6, fibro-
blast growth factor or CXCL10, which may contribute to the
stability of JAK2 phosphorylation [71].
To improve JAK2 inhibition, various strategies are being
tested. Synthesis of a JAK2V617F specific inhibitor would
likely improve JAK2 inhibition in MPN cells while sparing
healthy JAK2WT hematopoietic stem and progenitor cells.
The addition of a PI3K inhibitor to ruxolitinib may improve
JAK inhibitor efficiency [72, 73]. Similarly, use of HSP inhib-
itors together with JAK inhibitors decreases JAK2 phosphor-
ylation and improves clinical signs of the disease including
fibrosis [74] .
Conclusion
While the molecular defects of BCR-ABL negative MPNs
have remained unsolved for almost a century, the past
10 years have seen the discovery of various mutations in
MPN, translating into the development of JAK inhibitors
in these diseases. While being a substantial improvement
in patients’ care and quality of life, these molecules none-
theless do not provide a cure to patients with MPN. A
new player recently emerged in a substantial fraction of
MPNs, CALR which upon insertions and deletions in its
last exon leads to novel proteins that drive ET and MF,
but apparently not - or very rarely - PV, and appear to
support pathologically persistent JAK2 and STAT5 activa-
tion. Whether mutated CALR proteins are secreted or act
only intracellularly remains to be determined. Further
studies will have to establish the mechanistic links be-
tween these mutants, their traffic and potential signaling
leading JAK-STAT activation, as well as their roles in
hematopoietic stem and progenitor cells, especially mega-
karyocytes. Understanding how all these mutations alter
or synergize with the epigenetic configuration will be key
issues to improve MPN therapy.
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